Bio-Rad Laboratories, Inc.BIONYSE

|||

Overview News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 64% recommend buying.

Consensus Rating

Buy

14 analysts·Moderate coverage

64%

Rating Distribution

Strong Buy

00%

Buy

964%

Hold

536%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see modest upside — consensus target 6% higher.

Bear Case

$340.00

+6%

Consensus

$340.00

+6%

Bull Case

$340.00

+6%

Price Range14 analysts

Low

Consensus

High

$340.00

Current Target

Current Price

$322.06

Upside to Target

$17.94

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$10.70(2 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+4.09%

EPS+12.04%

FY2028

Rev+5.03%

EPS+15.51%

Earnings Surprises

Beat rate:75%(9/12 quarters)

Avg surprise:+16.3%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Oct 30, 2025Wells Fargo

Bio-Rad price target raised to $340 from $265 at Wells Fargo

Target:$340.00

+6.4%from $319.47

Oct 1, 2024Citigroup

Citi Upgrades Bio-Rad Labs (BIO) to Buy

Target:$400.00

+18.1%from $338.58

Dec 7, 2022RBC Capital

RBC Capital Initiates Coverage On Bio-Rad Laboratories with Outperform Rating, Announces Price Target of $565

Target:$565.00

+41.4%from $399.59

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance